sildenafil citrate - Profile

What are the generic drug sources for sildenafil citrate and what is the scope of patent protection?

Sildenafil citrate is the generic ingredient in five branded drugs marketed by Ibsa, Viatris, Ajanta Pharma Ltd, Alkem Labs Ltd, Amneal Pharms, Aurobindo Pharma Ltd, Chartwell Rx, Granules, Hetero Labs Ltd V, Invagen Pharms, Lupin, MSN, Novitium Pharma, Taro, Teva Pharms Usa, Tris Pharma Inc, Zydus Lifesciences, Eugia Pharma, Cmp Dev Llc, Actavis Grp Ptc, Amneal Pharms Ny, Apotex Corp, Appco, Cadila Pharms Ltd, Jubilant Generics, Macleods Pharms Ltd, Mylan, Mylan Pharms Inc, Perrigo R And D, Reyoung, Rubicon Research, Sunshine, Teva, Teva Pharms, Torrent, Torrent Pharms Ltd, Umedica, and Watson Labs Inc, and is included in fifty-five NDAs. There are six patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Sildenafil citrate has twenty-one patent family members in sixteen countries.

There are three tentative approvals for this compound.

Summary for sildenafil citrate

International Patents:	21
US Patents:	6
Tradenames:	5
Applicants:	38
NDAs:	55
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for sildenafil citrate

Generic filers with tentative approvals for SILDENAFIL CITRATE

Applicant	Application No.	Strength	Dosage Form
		100MG	TABLET; ORAL
		50MG	TABLET; ORAL
		25MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for SILDENAFIL CITRATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIAGRA	Tablets	sildenafil citrate	25 mg and 50 mg	020895	1	2004-11-19
VIAGRA	Tablets	sildenafil citrate	100 mg	020895	1	2004-10-25

US Patents and Regulatory Information for sildenafil citrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ibsa	VYBRIQUE	sildenafil citrate	FILM;ORAL	210858-001	Dec 16, 2025		RX	Yes	No	11,123,287		Y
Ibsa	VYBRIQUE	sildenafil citrate	FILM;ORAL	210858-001	Dec 16, 2025		RX	Yes	No
Ibsa	VYBRIQUE	sildenafil citrate	FILM;ORAL	210858-002	Dec 16, 2025		RX	Yes	No	11,123,287		Y
Ibsa	VYBRIQUE	sildenafil citrate	FILM;ORAL	210858-002	Dec 16, 2025		RX	Yes	No
Ibsa	VYBRIQUE	sildenafil citrate	FILM;ORAL	210858-003	Dec 16, 2025		RX	Yes	No	11,123,287		Y

International Patents for sildenafil citrate

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2900215
European Patent Office	3731870	FORMULATIONS ORALES LIQUIDES POUR INHIBITEURS DE PDE V (LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS)
China	111683683	PDE V抑制剂的液体口服制剂 (LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS)
Singapore	11202006080S	LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS
Denmark	2900215

Supplementary Protection Certificates for sildenafil citrate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0463756	99C0007	Belgium		PRODUCT NAME: SILDENAFIL, NATL REGISTRATION NO/DATE: EU/1/98/077/001 19980914; FIRST REGISTRATION: CH 54642 19980622
0463756	C990005	Netherlands		PRODUCT NAME: SILDENAFIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT, IN HET BIJZONDER SILDENAFIL CITRAAT; NATL REGISTRATION NO/DATE: EU/1/98/077/001-012 19980914; FIRST REGISTRATION: CH 54642 19980622
0463756	5/1999	Austria		PRODUCT NAME: ''SILDENAFIL'' UND DESSEN PHARMAZEUTISCH ANNEHMBAREN SALZE, EINSCHLIESSLICH DES CITRATS; NAT. REGISTRATION NO/DATE: EU/1/98/077/001 - EU/1/98/077/012 19980914; FIRST REGISTRATION: LI 54642 01-54642 03 19980622
0463756	SPC/GB99/004	United Kingdom		PRODUCT NAME: SILDENAFIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE CITRATE SALT; REGISTERED: CH 54642 19980622; UK EU/1/98/077/001 19980914; UK EU/1/98/077/002 19980914; UK EU/1/98/077/003 19980914; UK EU/1/98/077/004 19980914; UK EU/1/98/077/005 19980914; UK EU/1/98/077/006 19980914; UK EU/1/98/077/007 19980914; UK EU/1/98/077/008 19980914; UK EU/1/98/077/009 19980914; UK EU/1/98/077/010 19980914; UK EU/1/98/077/011 19980914; UK EU/1/98/077/012 19980914

Sildenafil Citrate: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Sildenafil citrate, marketed primarily under the brand name Viagra, is a PDE5 inhibitor used for erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). Since its initial approval in 1998, the drug's market landscape has evolved amid patent expirations, generic competition, and expanding therapeutic indications. This analysis explores current investment scenarios, market dynamics, and future financial trajectories for sildenafil citrate, emphasizing key factors influencing growth, challenges, and profitability.

---

1. Investment Overview

Aspect	Details
Market Size (2022)	Global ED drug market valued at approximately $4.0 billion, with sildenafil accounting for a dominant share (~75%) prior to generic entries (Statista, 2022).
Patent Status	Original patents expired in most regions by 2013–2015, leading to widespread generic manufacturing.
Current Investment Climate	Focus on delineating niche markets, new indications, and regional expansion to sustain profitability.

Investors interested in sildenafil face a matured market characterized by mature revenue streams from branded and generic products, with potential growth through new clinical applications and regional market penetration.

---

2. Market Dynamics

2.1 Patent Expiration and Generic Competition

Year	Event	Impact
2013–2015	Patent expirations in US, EU	Surge in generic sildenafil availability, reducing prices by up to 80% (IMS Health, 2016).
2016 onward	Entry of multiple generics	Erosion of brand dominance, intensifying price competition.

Despite patent expiration, brand manufacturers maintain market share via:

• Pricing strategies.
• Brand loyalty.
• Extension of indications (e.g., PAH, altitude sickness).
• Patent opportunities for formulation improvements and delivery mechanisms.

2.2 Expanding Therapeutic Indications

Indication	Status	Impact
Erectile Dysfunction	Established	Core revenue generator.
Pulmonary Arterial Hypertension	Approved since 2005	Niche but consistent revenue.
Altitude Sickness	Approved in certain markets	Emerging opportunity to broaden use cases.
Female Sexual Dysfunction	Under investigation	Potential future market expansion.

Innovations around these indications can create new revenue streams for existing formulations.

2.3 Regional Market Variability

Region	Market Share (2022)	Key Factors	Challenges
North America	~45%	High acceptance, insurance coverage	Patent expiry, price competition
Europe	~25%	Well-established generics market	Regulatory variances
Asia-Pacific	~20%	Growing awareness, aging population	Regulatory hurdles, pricing sensitivity
Latin America & Africa	~10%	Emerging markets	Distribution, affordability

Growth strategies involve tailored marketing, local partnerships, and pricing adjustments aligned with regional economics.

2.4 Pricing and Reimbursement Trends

Trend	Description	Impact
Price Compression	Due to generic competition	Margin erosion
Reimbursement Policies	Favor generics	Favorable for affordability but pressure on brand margins
OTC Availability	Limited	Regulators cautious; potential future shifts

---

3. Financial Trajectory

3.1 Revenue Projection (2022–2027)

Year	Estimated Revenue (USD billion)	Key Drivers
2022	4.0	Market penetration, generics
2023	3.85	Price erosion, patent limitations
2024	3.7	Market saturation, competition intensifies
2025	3.6	Innovations and new indications emerge
2026	3.65	Regional expansion
2027	3.7	Stabilization, niche growth

Note: Slight recovery possible through differentiation, new delivery systems, or expanded indications.

3.2 Cost Structure Analysis

Cost Category	Estimated Percentage of Revenue	Notes
Manufacturing	10–15%	Economies of scale reduce costs
R&D	5–10%	Focus on new indications and formulations
Marketing & Distribution	15–20%	Maintaining market share amid competition
Regulatory & Compliance	5%	Ongoing licensure and patent filings

3.3 Profit Margin Outlook

Scenario	Gross Margin	Operating Margin	Reasons
Conservative	45–50%	15–20%	High generic competition, pricing pressure
Optimistic	50–55%	20–25%	Successful niche expansion, patent extensions

3.4 Investment Risks

Risk Factor	Description	Mitigation Strategies
Patent Expiry	Lowering exclusivity	Diversify indications, innovate formulations
Price Competition	Market saturation	Focus on regional markets with less competition
Regulatory Changes	Stricter access regulations	Engage early in regulatory pathways
Clinical Failures	Development of new indications	Invest in robust clinical trials

---

4. Comparative Analysis with Similar Drugs

Drug	Market Share (2022)	Patent Status	Major Markets	Revenue Trends	Key Differentiators
Sildenafil (Viagra)	Dominant pre-generics	Patents expired	US, EU, Asia	Declining but steady	Established safety profile, brand recognition
Tadalafil (Cialis)	Growing	Patent until 2023	Global	Increasing due to long-acting formulation	Longer half-life, daily dosing option
Vardenafil (Levitra)	Niche	Patent expired	Select markets	Stable but declining	Similar efficacy, different side effect profile

Understanding these comparative dynamics helps position sildenafil within the broader ED pharmacotherapy landscape.

---

5. Key Market Players and Portfolio Strategies

Company	Strategy	Key Products	Market Position
Pfizer	Legacy brand, innovation in formulation	Viagra, Sildenafil Citrate Effervescent	Market leader historically, facing patent expiry
Teva, Sandoz, Mylan	Generics	Sildenafil tablets	Cost leadership, widespread availability
Bayer	PAH indications	Adempas	Niche, complementary therapy
Others	R&D investors	Investigational indications	Diversification efforts

Strategic alliances often focus on licensing, regional expansion, and R&D collaborations.

---

6. Regulatory and Policy Environment

Jurisdiction	Regulatory Landscape	Impact	Recommendations
US	FDA approvals, patent expiries	Market saturation post-patent	Focus on generics, biosimilars
EU	EMA regulations, patent timelines	Similar to US	Emphasize innovative marketing
China/India	Stringent approvals, price controls	Largest regional markets	Local manufacturing partnerships
Emerging Markets	Variable enforcement	Growth potential	Tailored marketing, affordability programs

Regulatory clarity influences availability and pricing strategies, critical for long-term planning.

---

7. Future Opportunities and Challenges

Opportunities	Challenges	Strategic Response
New indications (e.g., female sexual dysfunction)	Clinical trial uncertainties	Invest in R&D, clinical validation
Novel formulations (e.g., slow-release, transdermal)	R&D costs, regulatory hurdles	Partner with innovative delivery firms
Regional expansion	Pricing pressures, regulatory hurdles	Focus on emerging markets
Digital health integrations (e.g., telemedicine support)	Data privacy, regulatory approval	Collaborate with tech firms

Maintaining a competitive edge requires continuous innovation and regional focus.

---

Key Takeaways

• Sildenafil citrate remains a cornerstone of ED therapy but faces decreased revenues due to patent expirations and generic competition.
• Market growth relies on expanding indications, innovative formulations, and regional strategies—particularly in emerging markets.
• Long-term profitability depends on balancing price pressures with differentiation, through clinical innovation and niche targeting.
• Risks include regulatory changes, market saturation, and clinical trial failures; strategic diversification attenuates these.
• Future growth opportunities hinge on developing new delivery systems, exploring new indications, and leveraging digital health integrations.

---

FAQs

Q1: How has patent expiration affected sildenafil's market profitability?
A: Patent expiration in 2013–2015 led to a significant price decline (~80%), increased generic competition, and eroded brand dominance. However, profitability persists through new indications, formulation innovations, and regional strategies.

Q2: What are the main growth drivers for sildenafil in the coming years?
A: Expansion of indications (e.g., female sexual dysfunction, PAH), novel delivery formats (e.g., transdermal patches), and regional market expansion—especially in Asia and Latin America.

Q3: How do regional policies impact sildenafil investments?
A: Variations in regulation, reimbursement, and patent enforcement shape market entry strategies, pricing, and profitability. Emerging markets present growth opportunities but require tailored approaches.

Q4: What are the most significant risks facing sildenafil investments?
A: Patent challenges, regulatory changes, price compression, and clinical trial failures for new indications pose notable risks, necessitating diversified strategic planning.

Q5: How does sildenafil compare to other ED drugs like tadalafil?
A: Sildenafil is often preferred for its rapid onset, but tadalafil offers longer duration, which influences competitive positioning. Market share dynamics depend on regional preferences and specific indications.

---

References

[1] Statista. (2022). Global erectile dysfunction market size.
[2] IMS Health. (2016). Impact of generic sildenafil on market pricing.
[3] U.S. Food and Drug Administration (FDA). (2005–2022). Drug approval history and patent statuses.
[4] European Medicines Agency (EMA). (2022). Regulatory updates on sildenafil indications.
[5] MarketWatch. (2023). Overview of the global ED devices and pharmaceuticals market.